Qingdao Baheal Medical INC. (SHE:301015)

Market Cap	11.95B +25.1%
Revenue (ttm)	7.45B -7.9%
Net Income	513.61M -13.0%
EPS	0.96 -12.8%
Shares Out	525.62M
PE Ratio	23.69
Forward PE	22.07
Dividend	0.57 (2.44%)
Ex-Dividend Date	Jun 1, 2026

Volume	5,021,400
Open	22.21
Previous Close	23.37
Day's Range	22.21 - 23.48
52-Week Range	17.41 - 32.38
Beta	0.47
Analysts	Strong Buy
Price Target	27.31 (+20.15%)
Earnings Date	Apr 29, 2026

About SHE:301015

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 3,064
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301015

Financial Performance

In 2025, SHE:301015's revenue was 7.51 billion, a decrease of -7.26% compared to the previous year's 8.09 billion. Earnings were 474.69 million, a decrease of -31.36%.